Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai regains control of ADC from BMS; RSV vaccine developers hit by declining expectations; and an interview with Amgen’s Ian Thompson.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 July 2024, including: US approval for Eli Lilly and Company’s Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai Co., Ltd. regains control of ADC from Bristol Myers Squibb Company; RSV vaccine developers hit by declining expectations; and an interview with Amgen, Inc.’s Ian Thompson.

This and all our other podcasts are available on the Citeline channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s" - Scrip, 3 July, 2024.)

(Also see "Big Pharma Leads Development Of Novel Antibody-Drug Conjugates" - Scrip, 28 June, 2024.)

(Also see "Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization" - Scrip, 1 July, 2024.)

(Also see "Moderna And GSK Hit By Declining RSV Vaccines Expectations" - Scrip, 28 June, 2024.)

(Also see "Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters" - Scrip, 28 June, 2024.)

Citeline · Scrip's Five Must-Know Things - 8 July 2024

Open Media

More from New Products

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By 

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.